Clinical Takeaway
In this Phase 3 randomized controlled trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated against placebo over a 12-week double-blind period with up to one year of follow-up. The trial design is among the most rigorous applied to a cannabis-based treatment for this condition to date. Results from this study will provide high-quality evidence on whether a standardized full-spectrum cannabis extract offers a meaningful, safe alternative to conventional pain medications for one of the most prevalent and treatment-resistant pain conditions worldwide.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous efficacy and safety data for a full-spectrum cannabis extract in chronic low back pain, a highly prevalent condition where current pharmacologic options demonstrate inadequate pain relief with significant adverse effect profiles. The 12-week double-blind design with extended open-label follow-up generates the level of evidence necessary to inform clinical decision-making and potential regulatory approval for cannabis-based therapeutics in this patient population. Given that CLBP affects over 500 million people globally and current treatments are limited by efficacy and safety concerns, a well-tolerated alternative with demonstrated efficacy would substantially expand therapeutic options for this debilitating condition.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔬 This phase 3 trial of a full-spectrum cannabis extract for chronic low back pain represents a meaningful step toward evidence-based cannabinoid therapeutics, though several practical considerations warrant cautious interpretation. The 12-week double-blind phase with over 800 participants provides reasonably robust data compared to much of the existing cannabis literature, yet we should recognize potential confounders including variability in cannabis chemotype potency, differences in patient expectations around botanical medicines, and the challenge of adequately blinding full-spectrum extracts with characteristic sensory profiles. The extended open-label phase, while valuable for long-term safety assessment, introduces bias that limits conclusions about sustained efficacy. Given the current gap in effective pharmacologic options for CLBP and the growing patient interest in cannabis, clinicians might consider this trial as one data point supporting cautious shared decision-making with appropriate candidates, while emphasizing that individual response remains highly variable and that cannabis should complement rather than replace comprehensive pain management including physical therapy and psychological approaches.
| |